Show simple item record

dc.contributor.authorWilkins, A
dc.contributor.authorMossop, H
dc.contributor.authorSyndikus, I
dc.contributor.authorKhoo, V
dc.contributor.authorBloomfield, D
dc.contributor.authorParker, C
dc.contributor.authorLogue, John P
dc.contributor.authorScrase, C
dc.contributor.authorPatterson, H
dc.contributor.authorBirtle, A
dc.contributor.authorStaffurth, J
dc.contributor.authorMalik, Z
dc.contributor.authorPanades, M
dc.contributor.authorEswar, C
dc.contributor.authorGraham, J
dc.contributor.authorRussell, M
dc.contributor.authorKirkbride, P
dc.contributor.authorO'Sullivan, J
dc.contributor.authorGao, A
dc.contributor.authorCruickshank, C
dc.contributor.authorGriffin, C
dc.contributor.authorDearnaley, D
dc.contributor.authorHall, E
dc.date.accessioned2016-01-06T10:35:40Zen
dc.date.available2016-01-06T10:35:40Zen
dc.date.issued2015-10-27en
dc.identifier.citationHypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. 2015: Lancet Oncol, 16(16):1605-16en
dc.identifier.issn1474-5488en
dc.identifier.pmid26522334en
dc.identifier.doi10.1016/S1470-2045(15)00280-6en
dc.identifier.urihttp://hdl.handle.net/10541/592939en
dc.description.abstractPatient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally fractionated or hypofractionated radiotherapy in the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP) trial.
dc.languageENGen
dc.language.isoenen
dc.rightsArchived with thanks to The Lancet. Oncologyen
dc.titleHypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.en
dc.typeArticleen
dc.contributor.departmentThe Institute of Cancer Research, London, UKen
dc.identifier.journalThe Lancet. Oncologyen
html.description.abstractPatient-reported outcomes (PROs) might detect more toxic effects of radiotherapy than do clinician-reported outcomes. We did a quality of life (QoL) substudy to assess PROs up to 24 months after conventionally fractionated or hypofractionated radiotherapy in the Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP) trial.


Files in this item

This item appears in the following Collection(s)

Show simple item record